Lipocine Inc. announced topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. In the Phase 3 study population of 90 patients with postpartum depression (PPD), LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60, and the primary endpoint was not met.
However, a post hoc analysis of 54 participants who had a history of psychiatric conditions showed more promising signals. In this subgroup, LPCN 1154 demonstrated nominally statistically significant and clinically meaningful reductions in HAM-D scores compared to placebo as early as hour 12 and sustained through day 30.
In the overall population, LPCN 1154 was well tolerated with a differentiated safety profile. No adverse event, including somnolence or dizziness, occurred in more than 5% of LPCN 1154-treated participants. No treatment-related severe or serious adverse events were reported, no cases of excessive sedation or loss of consciousness were observed, and no treatment-related discontinuations occurred.
Based on the results of the post hoc analysis in participants with a history of psychiatric conditions, the company applied for breakthrough therapy and fast track designations for LPCN 1154 in patients with PPD. While waiting for FDA feedback on such designations, the company plans to preserve capital and evaluate options including continued development of LPCN 1154, potential submission of a validation study protocol, development of other product candidates, strategic transactions, and partnerships.
Postpartum depression is a major depressive disorder with onset during pregnancy or within four weeks of delivery, with symptoms potentially persisting up to 12 months after childbirth. Survey results indicate that obstetricians believe approximately 20-40% of their patients may suffer from PPD.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.prnewswire.com/news-releases/lipocine-reports-topline-safety-and-efficacy-results-for-lpcn-1154-in-patients-with-postpartum-depression-302732160.html